A single arm open label non-comparative Phase-I study to evaluate safety, reactogenicity and immunogenicity of single intramuscular dose of 14-valent pneumococcal polysaccharide conjugate vaccine (without preservative) of Biological E. Limited in 18-45 year-old healthy adults. - None
Latest Information Update: 21 Jan 2020
At a glance
- Drugs Pneumococcal conjugate vaccine 14-valent - Biological E Limited (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; First in man
- Sponsors Biological E Limited
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 14 Dec 2017 New trial record